Pvlearning: herramienta web para la enseñanza de la energía solar fotovoltaica

En este trabajo, se describe la web www.pvlearning.com, desarrollada en la Universidad de Alcalá para la enseñanza de la energía solar fotovoltaica. PVLEARNING asiste al alumno en la realización de tareas como la evaluación de la radiación solar disponible, la selección de los componentes del sistema, la configuración de éstos y la estimación del rendimiento global y la energía total producida. Frente a otros programas de simulación, la plataforma presenta la novedad de estar enfocada al aprendizaje de la ingeniería de proyectos, sin por ello perder todo el rigor y la funcionalidad necesarios en este tipo de simuladores.This work describes the web www.pvlearning.com, which has been developed at the Universidad de Alcalá for photovoltaic solar energy teaching. PVLEARNING assists the student in tasks such as the evaluation of the solar radiation, the selection of the system components, the configuration of the solar generator and the estimation of the performance ratio, the final yield and the total energy production. In contrast to other simulation programs, the platform has the novelty of being focused on the learning of project engineering, without losing the accuracy and functionality which is required in this kind of simulator

First universal newborn screening program for severe combined immunodeficiency in Europe: two-years' experience in Catalonia (Spain)

Newborn screening; Severe combined immunodeficiency; T-cell receptor excision circlesCribratge de nadons; Immunodeficiència combinada greu; Cercles d'excisió de receptors de cèl·lules TCribado de recién nacidos; Inmunodeficiencia combinada grave; Círculos de escisión de receptores de células TSevere combined immunodeficiency (SCID), the most severe form of T-cell immunodeficiency, can be screened at birth by quantifying T-cell receptor excision circles (TRECs) in dried blood spot (DBS) samples. Early detection of this condition speeds up the establishment of appropriate treatment and increases the patient's life expectancy. Newborn screening for SCID started in January 2017 in Catalonia, the first Spanish and European region to universally include this testing. The results obtained in the first 2 years of experience are evaluated here. All babies born between January 2017 and December 2018 were screened. TREC quantification in DBS (1.5 mm diameter) was performed with the Enlite Neonatal TREC kit from PerkinElmer (Turku, Finland). In 2018, the retest cutoff in the detection algorithm was updated based on the experience gained in the first year, and changed from 34 to 24 copies/μL. This decreased the retest rate from 3.34 to 1.4% (global retest rate, 2.4%), with a requested second sample rate of 0.23% and a positive detection rate of 0.02%. Lymphocyte phenotype (T, B, NK populations), expression of CD45RA/RO isoforms, percentage and intensity of TCR αβ and TCR γδ, presence of HLA-DR+ T lymphocytes, and in vitro lymphocyte proliferation were studied in all patients by flow cytometry. Of 130,903 newborns screened, 30 tested positive, 15 of which were male. During the study period, one patient was diagnosed with SCID: incidence, 1 in 130,903 births in Catalonia. Thirteen patients had clinically significant T-cell lymphopenia (non-SCID) with an incidence of 1 in 10,069 newborns (43% of positive detections). Nine patients were considered false-positive cases because of an initially normal lymphocyte count with normalization of TRECs between 3 and 6 months of life, four infants had transient lymphopenia due to an initially low lymphocyte count with recovery in the following months, and three patients are still under study. The results obtained provide further evidence of the benefits of including this disease in newborn screening programs. Longer follow-up is needed to define the exact incidence of SCID in Catalonia

Estandarización nacional del método de conductividad eléctrica para analizar el vigor de semillas en girasol

Objetivos del IIPAAS: Objetivo general: Validar a nivel nacional el test de conductividad eléctrica para medir el vigor en semillas de girasol. Objetivos específicos: 1. Confirmar la clasificación del vigor en base al test de CE propuesta en los estudios precedentes. 2. Evaluar la exactitud, reproducibilidad y repetibilidad del test de CE entre y dentro de los laboratorios participantes. 3. Confeccionar un protocolo nacional como paso previo para ser propuesto al Comité de Vigor de la ISTA

Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugsThis work was financially supported by the Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government: (grant: ED431B 2020/43), Centro Singular de Investigación de Galicia accreditation 2019–2022 (ED431G 2019/03), Ministerio de Ciencia e Innovación (PID2020-113430RB-I00) and the European Regional Development Fund (ERDF)S

A full characterization of the supermassive black hole in IRAS 09149–6206

We present new broad-band X-ray observations of the type-I Seyfert galaxy IRAS 09149–6206, taken in 2018 with XMM–Newton, NuSTAR, and Swift. The source is highly complex, showing a classic ‘warm’ X-ray absorber, additional absorption from highly ionized iron, strong relativistic reflection from the innermost accretion disc and further reprocessing by more distant material. By combining X-ray timing and spectroscopy, we have been able to fully characterize the supermassive black hole in this system, constraining both its mass and – for the first time – its spin. The mass is primarily determined by X-ray timing constraints on the break frequency seen in the power spectrum, and is found to be log [M_(BH)/M_⊙] = 8.0 ± 0.6 (1σ uncertainties). This is in good agreement with previous estimates based on the H α and H β line widths, and implies that IRAS 09149–6206 is radiating at close to (but still below) its Eddington luminosity. The spin is constrained via detailed modelling of the relativistic reflection, and is found to be a∗ = 0.94^(+0.02)_(−0.07) (90 per cent confidence), adding IRAS 09149–6206 to the growing list of radio-quiet active galactic nuclei (AGNs) that host rapidly rotating black holes. The outflow velocities of the various absorption components are all relatively modest (v_(out) ≲ 0.03c), implying these are unlikely to drive significant galaxy-scale AGN feedback

Excitotoxic inactivation of constitutive oxidative stress detoxification pathway in neurons can be rescued by PKD1

Excitotoxicity, a critical process in neurodegeneration, induces oxidative stress and neuronal death through mechanisms largely unknown. Since oxidative stress activates protein kinase D1 (PKD1) in tumor cells, we investigated the effect of excitotoxicity on neuronal PKD1 activity. Unexpectedly, we find that excitotoxicity provokes an early inactivation of PKD1 through a dephosphorylation-dependent mechanism mediated by protein phosphatase-1 (PP1) and dual specificity phosphatase-1 (DUSP1). This step turns off the IKK/NF-κB/SOD2 antioxidant pathway. Neuronal PKD1 inactivation by pharmacological inhibition or lentiviral silencing in vitro, or by genetic inactivation in neurons in vivo, strongly enhances excitotoxic neuronal death. In contrast, expression of an active dephosphorylation-resistant PKD1 mutant potentiates the IKK/NF-κB/SOD2 oxidative stress detoxification pathway and confers neuroprotection from in vitro and in vivo excitotoxicity. Our results indicate that PKD1 inactivation underlies excitotoxicity-induced neuronal death and suggest that PKD1 inactivation may be critical for the accumulation of oxidation-induced neuronal damage during aging and in neurodegenerative disorders